Supporting Information

Linking Design and Properties of Purine-Based Donor-Acceptor Chromophores as Optoelectronic Materials

Graham S. Collier,† Lauren A. Brown,† Evan S. Boone,‡ Meesha Kaushal,§ M. Nance Ericson,§ Michael G. Walter,§ Brian K. Long,† and S. Michael Kilbey II†‡*

†Department of Chemistry, University of Tennessee, Knoxville, Tennessee 37996, United States

‡Department of Chemical and Biomolecular Engineering, University of Tennessee, Knoxville, Tennessee 37996, United States

§Department of Chemistry, University of North Carolina at Charlotte, Charlotte, North Carolina, 28223, United States

#Electrical and Electronics Systems Research Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, United States

Table of Contents

Synthesis of new compounds………………………………………………………………………S2-S3

1H and 13C NMR spectra of compounds…………………………………………………….S4-S7

Thermogravimetric Analysis of compounds…………………………………………………S8-S9

Absorption Measurements and Beer’s Law plots……………………………………..S10-S12

Cyclic Voltammetry………………………………………………………………………….S13-S14

Frontier Molecular Orbital Plots…………………………………………………………..S15-S17
Synthesis of 6-bromo-9-ethylhexyl-purine

A solution of 6-bromopurine (3.000 g, 15.07 mmol) and potassium carbonate (6.25 g, 45.22 mmol) in DMF (100 mL) was prepared in a 250 mL 3-neck round-bottom flask equipped with a Teflon stir bar and the resulting mixture was stirred for 20 min. Ethylhexyl-bromide (5.36 mL, 30.15 mmol) was then added and the reaction mixture was stirred for 24 h. After 24 h, the reaction mixture was poured into DCM (50 mL), washed with H2O (3×100 mL), and the combined organic layers were dried with MgSO4 and filtered. The crude product was purified by flash chromatography on silica gel using hexanes and ethyl acetate (4:1 v/v). The collected fractions were dried, yielding a white solid (68% yield). 1H NMR (500 MHz, CDCl3), δ (ppm): 0.85-0.95 (m) 1.20-1.36 (m), 1.62 (br singlet), 1.91-2.03 (m), 4.18 (d, 2H, CH2), 8.08 (s, 1H, purine H), 8.70 (s, 1H, purine H). 13C NMR (500 MHz, CDCl3), δ (ppm): 10.39, 13.93, 22.82, 23.67, 28.35, 30.31, 39.75, 47.89, 134.00, 143.07, 145.33, 150.92, 151.84. AccuTOF DART (ESI): calc’d [M+H]+: 310.079, found [M+H]+: 310.080.

General Stille Cross-Coupling Procedure

6-bromo-9-ethylhexyl-purine (2 equiv.), the distannyl monomer (1 equiv.), and Pd(PPh3)4 (5 mol. %) were added to a single-neck 15 mL round bottom flask equipped with a Teflon stir bar and sealed with a rubber septa. The atmosphere was rendered inert via three evacuation and refill cycles with argon. Degassed toluene was added via syringe under an argon atmosphere and the reaction flask was placed in an oil bath set to 100 °C and the mixture was stirred for 18-24 h. After the allotted reaction time, the toluene was removed and the crude mixture was dissolved in DCM. The crude mixture was then passed through a pad of celite to remove palladium. The filtrate was then concentrated in vacuo and the desired product was purified via column chromatography.

P-BDT-P: Mobile phase: 6:1 v/v hexanes:ethyl acetate. Orange solid. 1H NMR (500 MHz, CDCl3), δ (ppm): 0.88 (t), 0.94-0.98 (m), 1.08 (t), 1.24-1.40 (m), 1.41-1.52 (m), 1.55-1.84 (m), 1.91-1.97 (m), 2.00-2.05 (m), 4.21 (d), 4.40 (d), 8.09 (s, 1H), 8.99 (s, 1H, purine H), 9.27 (s, 1H, purine H). 13C NMR (500 MHz, CDCl3), δ (ppm): 10.44, 11.41, 13.96, 14.19, 22.90, 23.17, 23.72, 23.87, 28.42, 29.29, 30.39, 30.50, 39.79, 40.79, 47.39,
75.55, 127.29, 129.88, 130.61, 134.01, 140.22, 145.05, 145.94, 149.79, 152.30, 152.42. AccuTOF DART (ESI): calc’d [M+H⁺]: 906.5376, found [M+H⁺]: 906.3566.

**P-Th-P:** Mobile phase: 2:1 v/v hexanes:ethyl acetate. Yellow powder. ¹H NMR (500 MHz, CDCl₃), δ (ppm): 0.88 (t), 0.94 (t), 1.24-1.39 (m), 2.01 (m), 4.21 (d), 8.10 (s), 8.77 (s, 1H, purine H), 8.94 (s, 1H, purine H). ¹³C NMR (500 MHz, CDCl₃), δ (ppm): 10.43, 13.97, 22.89, 23.71, 28.40, 30.36, 39.75, 47.40, 129.26, 133.37, 144.40, 144.93, 149.51, 152.42, 152.61. AccuTOF DART (ESI): calc’d [M+H⁺]: 544.3096, found [M+H⁺]: 544.3086.

**P-TBTT-P:** Mobile phase: 100% DCM. Red solid. ¹H NMR (500 MHz, CDCl₃), δ (ppm): 0.88 (t), 0.95 (t), 1.24-1.40 (m), 1.60 (s, br), 2.01 (m), 4.22 (d), 8.06 (s, 2H, purine H), 8.09 (s, 2H, purine H), 8.31 (d, 2 H, thiophene H) 8.73 (d, 2H, thiophene H), 8.94 (s, 2H, BT H). ¹³C NMR (500 MHz, CDCl₃), δ (ppm): 10.42, 13.97, 22.89, 23.71, 28.39, 30.36, 39.72, 47.39, 120.63, 126.08, 128.93, 129.20, 133.27, 140.89, 143.94 144.78, 149.49, 152.37, 152.44. AccuTOF DART (ESI): calc’d [M+H⁺]: 761.2990, found [M+H⁺]: 761.2956.
NMR Spectroscopy

**Figure S1.** $^1$H NMR spectrum (500 MHz, 25 °C, CDCl₃) of 6-bromo-9-ethylhexylpurine; δ (ppm): 0.85-0.95 (m), 1.20-1.36 (m), 1.62 (br singlet), 1.91-2.03 (m), 4.18 (d, 2H, CH₂), 8.08 (s, 1H, purine H), 8.70 (s, 1H, purine H).

**Figure S2.** $^{13}$C NMR spectrum (500 MHz, 25 °C, CDCl₃) of 6-bromo-9-ethylhexylpurine; δ (ppm): 10.39, 13.93, 22.82, 23.67, 28.35, 30.31, 39.75, 47.89, 134.00, 143.07, 145.33, 150.92, 151.84.
Figure S3. $^1$H NMR spectrum (500 MHz, 25 °C, CDCl$_3$) of P-BDT-P; $\delta$ (ppm): 0.88 (t), 0.94-0.98 (m), 1.08 (t), 1.24-1.40 (m), 1.41-1.52 (m), 1.55-1.84 (m), 1.91-1.97 (m), 2.00-2.05 (m), 4.21 (d), 4.40 (d), 8.09 (s, 1H), 8.99 (s, 1H, purine H), 9.27 (s, 1H, purine H).

Figure S4. $^{13}$C NMR spectrum (500 MHz, 25 °C, CDCl$_3$) of P-BDT-P; $\delta$ (ppm): 10.44, 11.41, 13.96, 14.19, 22.90, 23.17, 23.72, 23.87, 28.42, 29.29, 30.39, 30.50, 39.79, 40.79, 47.39, 75.55, 127.29, 129.88, 130.61, 134.01, 140.22, 145.05, 145.94, 149.79, 152.30, 152.42.
Figure S5. $^1$H NMR spectrum (500 MHz, 25 °C, CDCl$_3$) of P-TBTT-P; δ (ppm): 0.88 (t), 0.95 (t), 1.24-1.40 (m), 1.60 (s, br), 2.01 (m), 4.22 (d), 8.06 (s, 2H, purine H), 8.09 (s, 2H, purine H), 8.31 (d, 2 H, thiophene H) 8.73 (d, 2H, thiophene H), 8.94 (s, 2H, BT H).

Figure S6. $^{13}$C NMR spectrum (500 MHz, 25 °C, CDCl$_3$) of P-TBTT-P; δ (ppm): 10.42, 13.97, 22.89, 23.71, 28.39, 30.36, 39.72, 47.39, 120.63, 126.08, 128.93, 129.20, 133.27, 140.89, 143.94 144.78, 149.49, 152.37, 152.44.
**Figure S7.** $^1$H NMR spectrum (500 MHz, 25 °C, CDCl$_3$) of P-Th-P; $\delta$ (ppm): 0.88 (t), 0.94 (t), 1.24-1.39 (m), 2.01 (m), 4.21 (d), 8.10 (s), 8.77 (s, 1H, purine H), 8.94 (s, 1H, purine H).

**Figure S8.** $^{13}$C NMR spectrum (500 MHz, 25 °C, CDCl$_3$) of P-Th-P; $\delta$ (ppm): 10.43, 13.97, 22.89, 23.71, 28.40, 30.36, 39.75, 47.40, 129.26, 133.37, 144.40, 144.93, 149.51, 152.42, 152.61.
Thermogravimetric Analysis

Figure S9. Thermogravimetric analysis of P-BDT-P ramping 20 °C to 800 °C at a rate of 10 °C/min. The mass loss at T_d is consistent with loss of ethylhexyloxy side chains from BDT.

Figure S10. Thermogravimetric analysis of P-TBTT-P ramping 20 °C to 800 °C at a rate of 10 °C/min. The degradation event is attributed to loss of the purine functionalities to generate Compound 3 (see Scheme 1 in Article) because the ethylhexyl-functionalized purines contribute ~60% of the mass of P-TBTT-P.
Figure S11. Thermogravimetric analysis of P-Th-P ramping 20 °C to 800 °C at a rate of 10 °C/min.
Figure S12. UV-Vis spectra (from 325-600 nm) at various concentrations (2.5-20 μM) of P-BDT-P in chloroform and the corresponding Beer’s Law plots using the absorbance maximums.
Figure S13. UV-Vis spectra (from 325-600 nm) at various concentrations (2.5-20 μM) of P-TBTT-P in chloroform and the corresponding Beer’s Law plots using the absorbance maximums.
Figure S14. UV-Vis spectra (from 325-600 nm) at various concentrations (2.5-20 μM) of P-Th-P in chloroform and the corresponding Beer’s Law plots using the absorbance maximums.
Cyclic Voltammetry

**Figure S15:** Cyclic voltammogram of P-BDT-P (0.01 mmol) recorded at a scan rate of 100 mV/s in dichloromethane (5 mL), (nBu)₄NPF₆ (0.20 M), versus Fc/Fc⁺.

**Figure S16:** Cyclic voltammogram of P-TBTT-P (0.01 mmol) recorded at a scan rate of 100 mV/s in dichloromethane (5 mL), (nBu)₄NPF₆ (0.20 M), versus Fc/Fc⁺.
Figure S17. Cyclic voltammogram of P-Th-P (0.01 mmol) recorded at a scan rate of 100 mV/s in dichloromethane (5 mL), (nBu)4NPF6 (0.20 M), versus Fc/Fc+.
Frontier Molecular Orbital Plots

Figure S18. Frontier molecular orbital plots of P-BDT-P.
Figure S19. Frontier molecular orbital plots of P-TBTT-P.
Figure S20. Frontier molecular orbital plots of P-Th-P.